Breast cancer is the leading cause of cancer deaths among Black women of all ages and is increasing in younger women in the U.S.
Since our inception in 1990, Black women continue to be diagnosed with aggressive, early onset, late stage breast cancers that result in reduced survival rates. Breast cancer is the leading cause of cancer deaths among Black women of all ages and is increasing in younger women in the U.S.
The African American Breast Cancer Alliance (AABCA) finds that the barriers, issues and myths that the founders discovered 25 years ago are still a battle. Fear of breast cancer is universal for all populations and ages. Believing in survival is an everyday challenge but it is possible despite the setbacks we face dealing with this disease.
AABCA’s mission is to help women cope with the fear of cancer and the side effects of treatments. Our monthly peer support group offers a safe place where participants have a chance to:
AABCA continues its goals and objectives of community-based initiatives geared towards the awareness of breast health, breast cancer disparities, and education for Black women and the community by working together:
It’s not easy, but hard work always pays off and that’s evident in the increasing number of African Americans living through breast cancer.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.